GlassScriptPhysician profile
Joanna Tyzack
NPI 1487659892
$7,262.66
in general payments reported to CMS, 2019-2025
56 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $525 · 2021: $746 · 2022: $1,123 · 2023: $1,433 · 2024: $1,118 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $632.92 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $472.46 | 2019-2025 | Synthroid |
| Novo Nordisk INC | $467.76 | 2019-2025 | Rybelsus, Ozempic, Sogroya |
| Sanofi-Aventis U.S. LLC | $336.50 | 2019-2024 | |
| Radius Health, INC. | $313.73 | 2019-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $301.02 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $276.64 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Corcept Therapeutics | $273.85 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.77 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $230.54 | 2019-2025 | Omnipod |
| Abbott Laboratories | $227.83 | 2019-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $211.91 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Alexion Pharmaceuticals, INC. | $208.69 | 2019-2025 | Strensiq |
| Dexcom, INC. | $207.91 | 2019-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $200.63 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Tyzack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.